Endodiabesity

The North West of England Endocrinology, Diabetes and Obesity Newsletter

Weighing Risks and Benefits of Liraglutide — The FDA’s Review of a New Antidiabetic Therapy

Posted by Angela Paisley on 18 February, 2010

http://content.nejm.org/cgi/content/full/NEJMp1001578?query=TOC

FDA’s summary with regards to approval of liraglutide. Discussion of the potential benefits of improved glycaemic control whilst highlighting potentially serious safety concerns.

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s